Photos of hepatitis Day in medical institutions:
On-site blood sampling for HBV RNA detection:
In order to further realize the "healthy Chinese Dream", Rendu people have been on the road. In 2021, RENDU BIOTECHNOLOGY was approved as the world's first commercially launching high-sensitivity assay for clinical HBV RNA detection and was included in the latest expert consensus. Serum HBV RNA can feedback the transcriptional activity of cccDNA, which can be used to monitor efficacy, predict the risk of relapse after drug withdrawal, and predict the efficacy of interferon in early stage. HBV RNA is closely related to the occurrence of HCC. It will contribute to the goal of eliminating hepatitis B in China in predicting liver cancer in high-risk patients, monitoring the efficacy of the whole course of disease, predicting the efficacy of antiviral response, and evaluating the efficacy of new hepatitis B drugs. HBV RNA Assay from RENDU BIOTECHNOLOGY uses direct quantification (SAT) technology, without DNase treatment, no loss of RNA, higher sensitivity, automatic detection, good repeatability, which is a more suitable method for HBV RNA detection.
Address：Block A, building 15, NO.528 Ruiqing Road, East District, Zhangjiang High Tech Park, Shanghai, P.R .China